<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Pataskar A</submitter><funding>European Research Council</funding><funding>KWF Kankerbestrijding</funding><pagination>502</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10239192</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69-74, 2015; Waldman et al., Nat Rev Immunol 20:651-668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named "neoantigen" (Schumacher and Schreiber, Science 348:69-74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely </pubmed_abstract><journal>BMC cancer</journal><pubmed_title>ABPEPserver: a web application for documentation and analysis of substitutants.</pubmed_title><pmcid>PMC10239192</pmcid><funding_grant_id>832844</funding_grant_id><funding_grant_id>13647</funding_grant_id><pubmed_authors>Montenegro Navarro J</pubmed_authors><pubmed_authors>Agami R</pubmed_authors><pubmed_authors>Pataskar A</pubmed_authors></additional><is_claimable>false</is_claimable><name>ABPEPserver: a web application for documentation and analysis of substitutants.</name><description>&lt;h4>Background&lt;/h4>Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69-74, 2015; Waldman et al., Nat Rev Immunol 20:651-668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named "neoantigen" (Schumacher and Schreiber, Science 348:69-74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-04T23:07:46.875Z</modification><creation>2025-04-04T23:07:46.875Z</creation></dates><accession>S-EPMC10239192</accession><cross_references><pubmed>37270525</pubmed><doi>10.1186/s12885-023-10970-8</doi></cross_references></HashMap>